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ABSTRACT
Background Outcomes for patients with chronic 
obstructive pulmonary disease (COPD) with persistent 
hypercapnic respiratory failure are improved by long- term 
home non- invasive ventilation (NIV). Provision of home- 
NIV presents clinical and service challenges. The aim 
of this study was to evaluate outcomes of home- NIV in 
hypercapnic patients with COPD who had been set- up at 
our centre using remote- monitoring and iVAPS- autoEPAP 
NIV mode (Lumis device, ResMed).
Methods Retrospective analysis of a data set of 46 
patients with COPD who commenced remote- monitored 
home- NIV (AirView, ResMed) between February 2017 and 
January 2018. Events including time to readmission or 
death at 12 months were compared with a retrospectively 
identified cohort of 27 patients with hypercapnic COPD 
who had not been referred for consideration of home- NIV.
Results The median time to readmission or death was 
significantly prolonged in patients who commenced home- 
NIV (median 160 days, 95% CI 69.38 to 250.63) versus 
the comparison cohort (66 days, 95% CI 21.9 to 110.1; 
p<0.01). Average time to hospital readmission was 221 
days (95% CI, 47.77 to 394.23) and 70 days (95% CI, 
55.31 to 84.69; p<0.05), respectively. Median decrease in 
bicarbonate level of 4.9 mmol/L (p<0.0151) and daytime 
partial pressure of carbon dioxide 2.2 kPa (p<0.032) in 
home- NIV patients with no required increase in nurse 
home visits is compatible with effectiveness of this service 
model. Median reduction of 14 occupied bed days per 
annum was observed per patient who continued home- NIV 
throughout the study period (N=32).
Conclusion These findings demonstrate the feasibility and 
provide initial utility data for a technology- assisted service 
model for the provision of home- NIV therapy for patients 
with COPD.
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) is the second most common cause 
of emergency hospital admission in the UK, 
accounting for over 1 million bed days at a 
cost to the National Health Service (NHS) of 
over £800 million a year.1 Around a third of 
those admitted to hospital following an exac-
erbation of COPD are readmitted within 90 
days, which is also strongly associated with 
post- discharge mortality.2 Avoiding COPD 
exacerbations and hospitalisations is noted to 
be a key priority by patients with COPD,3 4 and 
targeting a reduction in these is necessary to 
address the substantial health and economic 
burden imposed by COPD.
The risk of hospital readmissions and further 
life- threatening events is particularly high 
among patients with a severe exacerbation of 
COPD that leads to hypercapnic respiratory 
failure.5 The first- line treatment for these 
patients in the acute setting is non- invasive 
ventilation (NIV), which has been shown to 
prevent intubation and invasive mechanical 
ventilation and reduce hospital mortality.6 7 
However, it was previously reported that more 
than 75% of patients treated with NIV for 
Key messages
 ► Remote- monitoring using an ‘auto- titrating’ mode of 
home non- invasive ventilation (NIV) in patients with 
chronic obstructive pulmonary disease (COPD) is 
feasible, with potential to achieve outcomes mirror-
ing those from randomised control trials
 ► Home- NIV supported with two- way remote moni-
toring and use of iVAPS- autoEPAP mode is feasible, 
with prolonged time to readmission or death within 
12 months versus a comparator group of patients 
noted in this retrospective observational study.
 ► The COVID- 19 pandemic has mandated remote- 
management for respiratory care where feasi-
ble. This is the first study to provide an approach, 
demonstrate feasibility and provide encouraging 
early utility data for a technology- assisted service 
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acute hypercapnic respiratory failure were readmitted 
and nearly 50% died within the first year after discharge.5
A growing area of interest to improve outcomes for 
patients with severe COPD focuses on the application 
of long- term NIV in the home setting. In a recent land-
mark study, Murphy et al showed that the addition of 
home- NIV to long- term home oxygen therapy in patients 
that remained severely hypercapnic 2–4 weeks after 
an exacerbation delayed and reduced hospital read-
missions at 12 months.8 A benefit on 12- month overall 
survival was noted in an earlier randomised controlled 
trial involving stable hypercapnic patients treated with 
home- NIV.9 The driver of clinical improvements across 
both studies can be attributed to higher inspiratory pres-
sures targeting a reduction in carbon dioxide (CO2) in 
patients who were persistently hypercapnic. A task force 
of the European Respiratory Society has since adopted 
home NIV as recommended treatment for patients with 
COPD presenting with persistent hypercapnic respira-
tory failure.10
Overall, the existing body of research suggests that 
there are some open questions with regards to patient 
selection and timing of home- NIV.11 12 For example, only 
5% of patients screened in home oxygen therapy- home 
mechanical ventilation (HOT- HMV) study were recruited 
to the trial, raising questions about the external validity 
of NIV randomised controlled trial (RCT) results. Many 
of the patients excluded from NIV RCTs have presen-
tations such as coexisting obesity, recurrent episodes of 
acute hypercapnic respiratory failure despite optimal 
management or suspected or confirmed symptomatic 
COPD- OSA (obstructive sleep apnoea) overlap for which 
home NIV provision is an accepted indication. Obtaining 
real- world experience data to determine whether bene-
ficial outcomes from home NIV COPD RCTs can be 
matched with routine clinical adoption is required.
The feasibility of delivering home- NIV to patients 
outside of controlled clinical trial settings also remains to 
be established. Provision for elective inpatient NIV initi-
ation and titration outside of tertiary centres and clin-
ical trial settings is limited. Patients with COPD generally 
wish to avoid hospitalisations, and severity of their illness 
limits capacity for outpatient attendances. Regular 
follow- up helps to monitor the effectiveness of ventilation, 
encourages treatment adherence and optimises patient 
comfort and ventilator settings, but realistic delivery 
of intensive follow- up is problematic.13 The COVID- 19 
pandemic has presented additional challenges including 
overall healthcare service pressures and capacity, social 
distancing requirements, need to minimise risk of noso-
comial COVID- 19 in vulnerable patient and infection 
control requirements for clinicians, with NIV classified 
as an aerosol generating procedure. There is therefore 
a requirement to develop and evaluate service models 
which can facilitate provision of home NIV for patients 
with COPD at scale, without variations of care.
It has been demonstrated that patients with COPD at 
high risk for exacerbations can be taught to self- manage 
when offered ongoing support.14 Early evidence that 
compares remotely monitored patients with COPD with 
usual face- to- face care is encouraging in terms of patient 
quality of life and number of hospital admissions.15 With 
the recent advent of two- way remote- monitoring, health-
care providers can view live NIV data from patients, 
adjust ventilator settings remotely and prioritise workflow 
to facilitate personalised care.
Given preceding equipoise, prior to 2017 we had only 
provided home NIV to patients with COPD at our centre 
on a highly selected case–case basis. Following publica-
tion of the HOT- HMV study8 NHS Greater Glasgow and 
Clyde (GG&C) developed and implemented an assistive 
technology supported service for patients with COPD 
requiring home NIV. Service is based at Queen Elizabeth 
University Hospital (QEUH) which is a large tertiary 
centre with 1677 acute beds, serving a referral popula-
tion of 1.2 million patients. Referrals for consideration of 
home NIV were taken from respiratory teams at QEUH 
and from associated general hospitals in the West of Scot-
land region. Patients with acute hypercapnic respiratory 
failure were not proactively ‘pulled’ into the service over 
the first year, pending acquisition of implementation- 
effectiveness feasibility experience.
We routinely use iVAPS- autoEPAP NIV mode (Lumis, 
ResMed) for home NIV at our centre. Use of iVAPS mode 
has been shown to reduce time required for satisfactory 
NIV set- up in patients with COPD.16 Additional advan-
tages include capability of the mode to adapt to patient’s 
fluctuating clinical status such as improvements post 
exacerbation. Auto- EPAP modes can potentially address 
coexisting OSA (there is a high prevalence of obesity 
in our population) and variable expiratory flow limita-
tion, which is emerging as important treatment target 
in COPD.17 Remote monitoring allows detection and 
management of excessive unintentional leaks and subop-
timal pressure support provision which were previously 
a concern for the continued use of volume- assured pres-
sure support NIV modes. It remains however essential to 
benchmark outcomes, to ensure that care- quality is main-
tained with this approach to NIV set- up.
For this evaluation, we retrospectively reviewed 
routinely available health record data from the patients 
with COPD who were commenced on remote- monitored 
NIV therapy over the first 12 months of this service. 
Our aim was to evaluate feasibility and acquire explor-
atory utility data from a real- world cohort of hypercapnic 
patients with COPD, who have a typical range of comor-
bidities which would have excluded many from NIV 
RCTs. We also had available routine health record data in 
a comparator cohort of patients from a 6- month period 
within 2017 who had received acute NIV for COPD at 
QEUH but had not been referred for consideration of 
home NIV. The primary outcome from our evaluation 
was median time to readmission or death over 12 months 
inpatients receiving home- NIV, with planned comparison 
of this outcome between patients who continued versus 
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and with patients in the comparator cohort. Data on 
respiratory- related hospital admissions, occupied bed 
days, respiratory nurse home visits and follow- up capillary 
blood gases was also available.
METHODS
Study design and patients
This study is part of programme of work analysing 
outcomes in a data set of patients with COPD provided 
by NHS GG&C Safe Haven. Local Privacy Advisory 
Committee approval was obtained for release of de- iden-
tified data for this study.
Two cohorts were sampled from the database as outlined 
in figure 1. The home- NIV cohort consisted of 42 consec-
utive patients with COPD who commenced home- NIV 
between 25 February 2017 and 25 January 2018 at the 
QEUH. COPD diagnosis was confirmed as per Global 
Obstructive Lung Disease (GOLD) guidelines, and was 
the primary diagnosis responsible for hypercapnic respi-
ratory failure in all patients in this cohort. Hypercapnic 
respiratory failure was defined as partial pressure of 
carbon dioxide (PCO2) >7 kPa at least 2 weeks after index 
acute exacerbation and/or presence of persisting hyper-
capnia across current and previous COPD episodes, with 
deferred NIV assessment for attempted follow- up post 
episode judged inappropriate.
Twenty- eight patients in this cohort continued opti-
mised home- NIV throughout the 12- month study period 
(‘NIV users’). NIV usage, mask leak and therapy param-
eters were within standard acceptable range throughout 
this follow- up period.
Fourteen patients discontinued home- NIV due to 
poor acceptance despite individualised interventions 
to optimise therapy during the study period (‘NIV 
non- users’).
The comparator cohort comprised 27 patients treated 
with acute NIV at the QEUH between March and 
November 2017 following a life- threatening exacerba-
tion of COPD that resulted in hypercapnic respiratory 
failure. This cohort had been created to consider patient 
numbers and potential care- quality gap addressable by 
‘pulling’ patients with hypercapnic respiratory failure in 
for home NIV consideration. Retrospective review noted 
that patients in this group were suitable for home- NIV 
but they were not referred to the home- NIV service 
during the follow- up period of this study. None of these 
patients crossed over to commence home NIV during the 
study’s observed follow- up period.
All patients in both cohorts were noted to be receiving 
guideline- based COPD care, including home oxygen 
therapy unless contraindicated. All patients with 
COPD are referred for pulmonary rehabilitation post 
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exacerbation, but data on uptake and completion is not 
available in the research data set.
Intervention
Since early 2017 we offer trialling home NIV to patients 
with COPD with persistent hypercapnia (PCO2 >7 kPa) 
at stable status, or during an acute episode if there has 
been recurrent hypercapnic respiratory failure where 
deferring commencing home NIV to outpatient review 
is judged impractical or unsafe by patient- clinician 
consensus. Often this decision to offer home NIV within 
an acute episode is supported by high serum bicarbonate 
levels (implying chronic hypercapnia) and/or presence 
of suspected or confirmed OSA overlapping with severe 
COPD. Inpatient sleep testing data are not routinely 
available at our referring general hospitals and when 
home NIV is clearly indicated and iVAPS- autoEPAP mode 
will be used for therapy, we do not undertake OSA quan-
tification as it extends hospital stay and does not alter 
immediate management. This is an extrapolation of the 
approach recommended in American Thoracic Society 
guidance on management of inpatient presentations of 
obesity hypoventilation syndrome.18
Patients in the home- NIV cohort were commenced 
on remote monitored home- NIV in iVAPS- autoEPAP 
mode (Lumis 150 ST- A, AirView, ResMed) if persisting 
hypercapnia was present at day case review 2–4 weeks 
following hospital discharge (n=14/42) or during the 
index hospital admission if persisting hypercapnia had 
been demonstrated across previous COPD episodes as 
per above noted criteria (n=28/42)
Patients initiated on home- NIV consented to their 
data being accessed and shared on the AirView platform 
by the necessary healthcare professionals. AirView data 
review was used to inform routine clinical care and iden-
tify NIV therapy issues (usage, leak) as well as ventila-
tion data patterns supporting optimised NIV provision. 
Remote- monitoring pathway is used to support day case 
NIV initiation, or early hospital discharge if NIV is initi-
ated during an inpatient episode. Remote- monitoring 
data are reviewed at day 1–2, day 5–7 and weekly there-
after, combined with individualised telephone or video 
consultation based initial follow- up. Remote- adjustments 
to iVAPS- autoEPAP NIV settings, adjustment to NIV 
interface and face–face at home or day case review 
arrangement are made where remote- monitoring and 
consultation data indicates a requirement. Stability is 
judged based on patient comfort and symptoms, accept-
able NIV usage durations, minimised unintentional 
leak and appropriate pressure support and other venti-
lator parameters. Clinic follow- up within 8–12 weeks 
including repeat capillary blood gases is scheduled for 
stable patients who can attend. Patients who are having 
persisting difficulties establishing home NIV despite 
remote- monitoring inputs are offered elective admission.
The online supplemental material provides an addi-
tional overview of the technology- assisted COPD NIV 
therapy protocol as implemented in NHS GG&C, with 
typical follow- up schedule and representative remote 
monitoring data.
Outcome measures
Baseline descriptive data were available including gender, 
age, body mass index (BMI), predicted forced expira-
tory volume in 1 s (FEV1)% as well as comorbidities that 
could potentially contribute to hypercapnia. The primary 
outcome was time to readmission or death, censored at 
date of admission, date of death or 25 January 2019. 
Secondary outcome measures included time to hospital 
admissions and overall survival in the home- NIV and 
comparator cohort.
Subgroup analyses of the home- NIV cohort explored 
differences between NIV users and NIV non- users in 
the primary and secondary outcome measures. Changes 
in number of hospital admissions, occupied bed days 
(OBDs) and respiratory nurse home visits were evalu-
ated in NIV users and NIV non- users before and after 
home- NIV. Changes in capillary blood gas PCO2 and 
bicarbonate were available for review in patients in the 
home- NIV cohort who were able to attend for follow- up.
Statistical analyses
Baseline characteristics of the study population are 
presented as mean (SD), median (IQR) or count 
(percentage), as appropriate. Primary and secondary 
study outcome measures were compared between the 
home- NIV and control cohort using Kaplan- Meier 
survival analysis and the Mantel- Cox log rank test.
Additional subgroup analyses compared primary 
and secondary outcome measures between the NIV 
user group and the NIV non- user group alongside the 
control cohort using Kaplan- Meier and Mantel- Cox 
tests. Changes in healthcare usage (number of hospital 
admissions, OBDs and respiratory nurse home visits) and 
capillary blood gas PCO2 and bicarbonate between NIV 
users, NIV non- users and the control cohort were anal-
ysed using Wilcoxon signed- rank test. Statistical analyses 
were conducted using IBM SPSS Statistics V.24 (IBM, 
New York, USA) and GraphPad Prism V.7.0 (GraphPad 
Software, San Diego, USA).
Patient and public involvement
Due to the nature of a retrospective analysis, the research 
was undertaken without patient involvement. Patients 
were not invited to comment on the study design and 
were not consulted to develop patient relevant outcomes, 
interpret the results or to contribute to the writing or 
editing of this document for readability or accuracy.
RESULTS
Baseline characteristics
Baseline characteristics are shown in table 1. Gender, 
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for a higher rate of men, lower BMI and a lower rate of 
notable comorbidities (suspected or confirmed overlap-
ping OSA, long- term opiate therapy) in the NIV non- 
user subgroup. All patients were ‘white British’ ethnicity, 
which is typical of the local population. The FEV1% 
predicted value was around 40% across all study groups, 
in line with a ‘severe’ classification of COPD(3) particu-
larly as in many patients the spirometry was an historical 
rather than contemporary result.
Time to readmission or death
The median time to readmission or death was signifi-
cantly prolonged in patients with persisting hypercapnic 
respiratory failure treated with home- NIV compared 
with the comparator cohort of hypercapnic patients with 
COPD (p<0.01, see figure 2A). Subgroup analyses showed 
significant differences between the NIV user subgroup 
versus both the NIV non- user group and the comparator 
cohort (both p<0.001). Improvement in time to readmis-
sion or death was not seen in patients who discontinued 
home- NIV (figure 2B). Table 2 summarises time to read-
mission or death for each group.
Median number of days to hospital readmission
Time to hospital readmission followed the same pattern 
as time to readmission or death. Median time to hospital 
readmission was 221 days for the home- NIV cohort 
(95% CI, 148 to 294) and 68 days (95% CI, 18 to 118; 
p<0.05) for the comparator cohort. Subgroup analyses 
showed that time to hospital readmission was signifi-
cantly improved in NIV- users when compared with NIV 
non- users and the control group (both p<0.01). There 
was no significant difference in these outcomes between 
the comparator patients and NIV non- users (p=0.38).
Overall survival
Twelve- month overall survival was 78.6% in the home- NIV 
cohort and 59.3% in the comparator cohort. Patients that 
continued to use home- NIV during the study period had 
a 12- month overall survival rate of 85.7%. Due to the low 
number of recorded mortality events, group differences 
were not statistically significant in the primary (p=0.066) 
or subgroup analyses (p=0.07).
Healthcare usage
Service usage in NHS GG&C by the home- NIV cohort 
in the 12 months prior to commencing home- NIV (pre- 
NIV) and the 12 months following initiation of home- NIV 
Table 1 Baseline characteristics
Total Comparator cohort Home- NIV
n n Total n NIV users n
NIV non- 
users n
Gender, n (% female) 49 M 20 F 
(28.9)
69 18 M 9 F 
(29.6)
27 30 M 12 F 
(28.5)
42 17 M 11 F 
(39.3)
28 13 M 1 F 
(7.1)
14
Mean age (SD) 64.55 (8.74) 69 66.48 (8.8) 27 63.31 (8.58) 42 62.54 (8.75) 28 64.86 (8.31) 14
Mean body mass index 
(SD)
27.6 (9.09) 53 26.02 (7.06) 27 29.23 (10.71) 26 32.23 (10.63) 16 21.41 (9.42) 10
FEV1% predicted mean 
(SD)




– – – – 14 (37.8) 37 11 (44) 25 3 (21.4) 12
FEV1, forced expiratory volume in 1 s; NIV, non- invasive ventilation .
Figure 2 Kaplan- Meier plot of time to readmission or 
death from study initiation to the end of study follow- up. 
(A) Primary analysis shows significant differences between 
the home- NIV and the comparator cohort. (B) Subgroup 
analyses showing improved time to readmission or death 
in patients who continued home NIV during study follow- 
up period compared with patients who discontinued home 
NIV and patients in the comparator cohort who had acute 
hypercapnic respiratory failure but were not referred for 
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(post- NIV) are outlined in table 3. A significant reduc-
tion in total number of admissions and OBDs is noted 
following initiation of home- NIV across all patients in 
the home- NIV cohort, but is particularly pronounced 
in NIV users (p<0.001, figure 3). The data equate to a 
median reduction of 14 OBDs per annum per patient 
who continued remote- monitored home- NIV. Require-
ments for respiratory nurse home visits did not change 
significantly following the initiation of home- NIV.
The reduction in admissions and OBDs in the home 
NIV user cohort also compares favourably with patients in 
the comparator cohort of patients who had acute hyper-
capnic respiratory failure but were not referred. There 
was no significant change in annualised admissions in the 
subsequent year, but a significant rise in annualised OBDs 
(median increase 11 days per patient, p=0.017) following 
the index acute hypercapnic respiratory failure episode 
in this cohort (online supplemental figure 4).
Blood gases
Capillary blood gas measurements were available in 21 
patients before and after home- NIV. Improvement in 
median PCO2 (2.2 kPa, p<0.05) and bicarbonate (4.9 
mmol/L, p<0.05) from baseline was noted at follow- up 
after initiation of home- NIV (figure 4).
DISCUSSION
In this report we summarise our approach with assistive 
technologies for home NIV, and present retrospec-
tively obtained outcome data in a cohort of patients 
with COPD with typical comorbidities who commenced 








follow- up, days 
(IQR)
479 (422) 69 486 (477) 27 479 (216) 42 478 (201) 28 441 (463) 14
Median time 
to readmission 
or death, days 
(95% CI)
92 (45 to 
139)
69 66 (18 to 
114)
27 171 (103 to 
239)*
42 379 (299 to 
459)†







101 (49 to 
153)
62 68 (18 to 
118)
25 221 (148 to 
294)*
37 387 (304 to 
470)†
26 45 (0 to 100) 11




46 (74) 62 20 (80) 25 26 (70) 37 16 (62) 26 10 (91) 11
*Significant differences home- NIV versus comparator cohort, p<0.05.
†Significant differences NIV users versus NIV non- users and comparator cohort, p<0.05.
NIV, non- invasive ventilation .
Table 3 Changes in healthcare usage before and after home- NIV
Pre- NIV Post- NIV n P value
Number of hospital admissions 127 67 42 0.0005
  NIV users 78 35 28 0.0015
  NIV non- users 49 32 14 0.1477
Occupied bed days 1131 414 42 <0.0001
  NIV users 775 230 28 0.0005
  NIV non- users 356 184 14 0.0254
Respiratory nurse home visits 69 67 24 0.9158
  NIV users 41 43 14 0.7134
  NIV non- users 28 24 10 0.8711
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treatment at our centre in the first 12 months following 
this service adoption. The data demonstrates the feasi-
bility of adopting two- way remote monitoring and 
volume- assured auto- EPAP mode to support home NIV 
provision to patients with COPD. Key findings are signifi-
cantly prolonged time to readmission or death in patients 
who commenced home NIV treatment, with fewer 
hospital readmissions and OBDs in the subsequent year 
in home- NIV users. Our experience provides early utility 
data for this service model, with outcomes which are in 
line with reported COPD- NIV RCT experience. Impor-
tantly, this data supports safety of this service model which 
minimises the need for elective inpatient admissions 
for home NIV set- up. These findings support further 
research and monitored adoption of technology- assisted 
home NIV service models using remote- monitoring and/
or ‘auto- NIV’ modes.
The adverse time to readmission or death and read-
mission frequency noted in the comparator cohort of 
patients who had had acute hypercapnic respiratory 
failure but not been referred for home NIV consider-
ation provides further support for the treatment benefit 
from home NIV. These patient cohorts are not directly 
comparable, which limits the inferences about home 
NIV treatment effect which can be made. There are 
also a number of potential biases. Additional comor-
bidity, COPD phenotype and management data are not 
available retrospectively. Patients were accrued over a 
single year which introduces seasonality and year–year 
variability of COPD admission confounders. In QEUH 
Figure 3 Changes in healthcare usage before and after home- NIV for NIV users (circle) and NIV non- users (triangle). Data on 
respiratory nurse home visits was not available in electronic health records for the 18 patients whose residence is outside our 
health board. NIV, non- invasive ventilation.
Figure 4 Changes in blood gas measurements at baseline and follow- up after home- NIV initiation in NIV users. Data 
availability limited to subset of patients who attended for face–face follow- up and had some or all components of post- NIV 
blood gas results inputted into electronic health record (including two patients who had PCO2 but not bicarbonate result 
available). Two patients had PCO2 <7 kPa at time of NIV initiation but had other standard indications to commence home NIV. 
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there is mandated nurse- specialist review of all admitted 
patients, with guideline- based care bundle provided: it is 
unlikely that there were major differences in approach to 
other components of COPD care. The observation that 
home NIV ‘treatment effect’ with reduction in annual-
ised admissions and OBDs persists when the cohort is 
compared with non- users and the non- referred patients 
accrued over a similar time period mitigates the potential 
time- series bias. In context, this data supports—in- line 
with clinical trial data—the likelihood of there being 
a positive treatment effect from home NIV as initiated 
and supported with assistive technologies at our centre 
and demonstrates that there is a care- quality outcome 
gap in patients with COPD who have acute hypercapnic 
respiratory failure but are not considered for home NIV 
at presentation or early follow- up. Based on this data 
we now proactively ‘pull’ out patients with COPD who 
require acute respiratory support at our centre in for 
follow- up and consideration of home NIV, and we are 
looking to further reduce variations in care with regional 
and national scale- up of this approach.
We have >10 years of experience with volume- assured 
pressure support and auto- EPAP NIV modes rapidly 
achieving successful control of hypercapnic respiratory 
failure regardless of the complexity of the underpinning 
aetiology and sleep- disordered breathing. Based on this 
experience and with high prevalence of obesity, OSA and 
comorbidities in our referral population our developed 
service approach therefore is to commence NIV treat-
ment for patients with COPD in iVAPS- auto- EPAP mode. 
We target symptom benefit, remote- monitored venti-
lation patterns and control of hypercapnic respiratory 
failure based on capillary blood gas results (see online 
supplemental data file), rather than targeting high pres-
sure support in spontaneous- timed NIV mode with trans-
cutaneous CO2 monitoring. Combining this ‘auto- NIV’ 
mode with two- way remote- monitoring mitigates the risk 
of unrecognised unintentional leak and inadequate pres-
sure support provision confounding treatment quality. 
Our observed satisfactory clinical outcomes and encour-
aging follow- up blood gas data with a median reduc-
tion in PCO2 of 2.2 kPa in patients who could attend for 
follow- up demonstrates feasibility and provides encour-
aging support on the quality and safety of this technology 
assisted NIV set- up service model. Further prospec-
tive scrutiny of this approach is required, and whether 
matched clinical outcomes and similar efficiency would 
be achieved with remote- monitored NIV using other 
ventilation modes and/or with supporting at home trans-
cutaneous or other modality of sleep breathing moni-
toring requires additional study.
The admission and survival results from our data are 
consistent with those in the HOT- HMV trial by Murphy 
et al with delayed and reduced hospital readmissions 
in hypercapnic patients with COPD who were referred 
for and continued home- NIV treatment.8 These find-
ings are encouraging. In addition to providing prelim-
inary support for the safety of our technology- assisted 
COPD- NIV service model, this data provides prelimi-
nary reassurance that benefits seen in clinical trials with 
home NIV in patients with COPD will be realised with 
real- world implementation. There are however a number 
of important differences comparing the HOT- HMV trial 
and this study, reflecting the real- world experience. Our 
cohort had accepted indications for starting home NIV, 
but our approach of pragmatically initiating home NIV 
during an acute episode if the patient’s presentation and 
shared decision- making render that appropriate are a 
potential confounder. Though our patients had sustained 
hypercapnic respiratory failure, it is possible that some 
of the subsequent improvement inpatient outcomes and 
blood gases may partly or completely reflect natural stabi-
lisation of their condition, rather than an NIV treatment 
effect. It is possible that deferring NIV initiation would 
have achieved similar outcomes in some of our treated 
patients, but that other patients would have then been 
lost to follow- up or sustained an adverse outcome.
There was less severe documented airflow obstruction 
in our cohort compared with HOT- HMV cohort, but we 
only had historical rather than contemporary spirometry 
for many patients. There was also a higher BMI and a 
higher rate of comorbidities potentially contributing to 
hypercapnic respiratory failure in this study’s patient 
cohort compared with HOT- HMV, particularly in the 
subgroup of patients who continued home NIV in the 
following year. Patients who discontinued home NIV 
during follow- up had lower mean BMI and comorbidity 
rates than those in the cohort who continued therapy. 
Remote- monitoring data supports our informal obser-
vations that patient’s discontinue home NIV based on 
shared decision- making despite close attention to address-
able factors and therapy optimisation during individual-
ised follow- up, rather than suboptimal NIV provision. It 
is possible that an alternative service model would reduce 
NIV discontinuation rates, and that there are patient 
characteristics which predict treatment failure and need 
for alternative management options. It could be that 
greater attention to patient knowledge and readiness for 
home NIV, additional support for treatment provision, 
alternative approaches to NIV optimisation or modified 
level of contact is required to improve home NIV uptake 
and retention. Our data provides a foundation to further 
explore these possibilities. Continued scrutinised adop-
tion of NIV remote- monitoring will provide data to help 
address these questions, and help establish service infra-
structure where implementation of additional assistive 
innovations such as prioritised access to NIV failure clin-
ical can be rapidly evaluated.19
In the HOT- HMV trial, home- NIV was noted to reduce 
exacerbation- related costs (by £1141 per case) and 
patient- reported costs (by £2337) relative to the control 
arm.20 NIV device cost and cost per physician visit had 
the greatest impact on cost per quality adjusted life year 
(QALY). The data from our study is in line with this, 
with a median reduction of 14 OBDs per annum and no 
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users. It is likely that a COPD home- NIV service model 
based on remote- monitoring and individualised follow- up 
which reduces hospital bed days, minimises physician 
visits and associated patient- carer travel costs will enhance 
cost- effectiveness. Further research and service adoption 
evaluations as this evidence- based intervention diffuses 
further into routine care are required to expand on the 
evidence for cost- effectiveness of home- NIV, explore the 
relative value of the assistive technology components and 
define whether a proactive COPD service model based 
on remote- monitoring is sustainable.
Among various patient groups using NIV at home, 
remote monitoring has been found to be non- inferior and 
at times more effective than usual face- to- face support, 
preferred by patients and associated with reduced health-
care utilisation.15 21–23 The additional channel of two- way 
patient engagement—that is, early intervention with an 
NIV therapy change to optimise settings based on remote- 
monitoring data—may prove particularly valuable to 
ensure continued treatment adherence. Our findings 
broadly complement those from recent study reported 
from the Netherlands, which demonstrated cost- effective 
provision of home initiation of NIV for stable hyper-
capnic patients with COPD using remote- monitoring of 
ventilator and transcutaneous CO2 data.
24 As key addi-
tions, our data suggest that it is feasible to use assistive 
technologies to commence and follow- up patients with 
home NIV when commencement is indicated at an acute 
episode as well as at stable status. Transcutaneous moni-
toring is only selectively undertaken at NIV initation 
and not routinely undertaken at follow- up in our service 
model. Provision of transcutaneous monitoring at scale 
presents substantial challenges and the positive clinical 
outcomes that we noted in follow- up of home NIV users 
provides some provisional reassurance about the safety 
of omitting this monitoring. Continued supervision of 
this approach with an expanded prospective cohort and 
continued reporting of outcomes to ensure safety and 
quality of home- NIV therapy, with continued evaluation 
of other surrogate endpoints for respiratory failure moni-
toring is required.
This study had several strengths, including the use of 
clinically meaningful outcomes and the real- world nature 
of the patient cohorts. However, we acknowledge several 
limitations. Treatment allocation was not randomised. 
Unrecognised confounding factors including differences 
in COPD severity, natural disease history, unquantified 
patient activation measures affecting continued NIV usage 
and potential heterogeneity of uptake of other compo-
nents of COPD care potentially bias the data. We also did 
not have complete data on demographics, comorbidities 
or provision of and adherence to other COPD treatments 
to ensure cohorts were otherwise matched. The statistical 
analyses of the subgroup analyses is exploratory due to 
the limited sample size and the potential issue of multiple 
testing. Finally, this study was not powered to find a differ-
ence in survival. While a survival benefit of home- NIV 
has been previously demonstrated in a similar patient 
population,9 clear evidence of improved survival is still 
lacking and should be investigated in larger prospective 
trials.
CONCLUSION
Patients with COPD with persistent hypercapnic respira-
tory failure have poor outcomes with limited treatment 
options available. In this study we confirm the feasibility of 
adopting a service model supported by assistive technolo-
gies—remote- monitoring and ‘auto- NIV’ mode—for the 
provision of home- NIV in a cohort of patients with COPD 
with comorbidities, as they typically present in clinical 
practice. Home- NIV prolonged the time to readmission 
or death within 12 months in treated patients, supporting 
the utility of this service model. In addition to being the 
outcomes that patients with COPD rate as most impor-
tant,4 exacerbation and hospitalisation avoidance address 
the substantial economic burden imposed by COPD. We 
noted reductions in healthcare usage among home- NIV 
users. The COVID- 19 pandemic has presented consider-
able challenges to home- NIV service provision. Our study 
provides data supporting the feasibility and utility of a 
service model based on outpatient or truncated inpatient 
NIV initiation using iVAPS- autoEPAP mode with remote 
monitoring based individualised follow- up. Continued 
prospective evaluation of safety and outcomes with use 
of these NIV technologies is required, but the advantages 
including reduced patient travel, reduced need for face–
face contact and reduced nosocomial COVID- 19 risk, 
with positive data supporting real- world positive impact 
of home NIV on COPD care- quality supports ongoing 
considered adoption of similar service models, with an 
approach as set out in the European Respiratory Society 
task force guidance on home NIV in COPD.10
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Supplementary Figure 1 
NHS GG&C breathing support service protocol for initiation of home NIV 
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Supplementary Figure 4 
Changes in healthcare usage in the year before and after index episode of acute hypercapnic respiratory 
failure (AHRF) in patients who were not referred for breathing support assessment and were not initiated 
on home NIV. There was no significant change in admission rates, but there was a significant rise in annual 
occupied bed days (median 11 days per patient) following the episode of AHRF. Data on respiratory nurse 
home visits was not available for this cohort. 
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